VEGFA and pulmonary edema: In contrast, others have suggested a pathological role for VEGF-A in ARDS with the development of pulmonary oedema and increased capillary permeability following adenoviral delivery of VEGF-A165a into the trachea of mice, an effect mitigated by anti-VEGF-A therapy [86,87].